Will Aptevo Therapeutics stock go up?

According to Danelfin AI, Aptevo Therapeutics has today an AI Score of 2/10 (Strong Sell rating), because its probability of beating the market in 3 months (41.20%) is -9.62% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for Aptevo Therapeutics stock?

The Aptevo Therapeutics target price is $4.49 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold Aptevo Therapeutics stock right now?

Aptevo Therapeutics has today a Strong Sell rating (AI Score 2/10), according to Danelfin AI. Its probability of beating the market in 3 months (41.20%) is -9.62% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether Aptevo Therapeutics stock is a good buy .

Is Aptevo Therapeutics undervalued right now?

Based on analysts, the average price target downside for Aptevo Therapeutics is 0.00% (1Y). According to Danelfin AI, Aptevo Therapeutics has today an AI Score of 2/10 (Strong Sell Rating).

What was the price range of Aptevo Therapeutics stock over the past 12 months?

The Aptevo Therapeutics stock price range over the past 12 months has been $3.96 - $75.06.

What is going on with Aptevo Therapeutics stock in the last 3 months?

The Aptevo Therapeutics stock performance in the last quarter has been +7.67%.

Does Aptevo Therapeutics offer dividend payments?

No, Aptevo Therapeutics does not currently pay dividends.

What is the current market capitalization of Aptevo Therapeutics?

Aptevo Therapeutics's market cap is $5.57M, as of 2026-07-03 08:00.

Aptevo Therapeutics Inc (APVO) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

APVO AI-Powered Stock Analysis

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Earnings Quality+1.57%
Stability and reliability of reported earnings
Size & Liquidity+0.35%
Company size and trading liquidity

Momentum-4.83%
Direction and strength of recent price movements
Volatility-2.47%
How much the stock price tends to fluctuate
Sentiment-1.77%
How analysts and the market view the stock
Growth-1.09%
Expected pace of revenue and earnings expansion
Valuation-1.04%
How the stock is priced relative to its fundamentals
Financial Strength-0.34%
Balance sheet strength and financial resilience

APVO probability advantage of beating the market (3M):

-9.62%

AI Score

Strong Sell

Aptevo Therapeutics (APVO) has an AI Score of 2/10 (Strong Sell) because, according to an overall analysis, it has a probability advantage of -9.62% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.82%) and the probability of APVO (41.20%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any US-listed stock of beating the market (3M)50.82%
APVO probability advantage of beating the market (3M)-9.62%
APVO probability of beating the market (3M)41.20%

APVO probability advantage of beating the market (3M): -9.62%

The AI-powered overall analysis of Aptevo Therapeutics (APVO) is based on the 29 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of APVO:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
Technical	Chart Pattern (252d)	figure_8	N/A	-2.16%
Technical	Chart Pattern (504d)	figure_6	N/A	-2.08%
Fundamental	Operating Cash Flow (Qtr Discrete)	-7.97		+1.57%
Sentiment	Institutional Ownership	6.05%		-1.31%
Fundamental	Basic EPS Consolidated	-6.31	N/A	-1.09%
Technical	ATR (180d Volatility)	5.84K		-0.94%
Technical	Normalized Average True Range (50d)	28.73%		-0.81%
Sentiment	Sentiment Impact (Long Tail)	-	N/A	+0.70%
Technical	Beta	1.63		-0.63%
Sentiment	Fear & Greed Index (CNN)	31	N/A	-0.60%
Fundamental	Upgrade to unlock			-0.58%
Technical	Upgrade to unlock			-0.54%
Technical	Upgrade to unlock			-0.54%
Technical	Upgrade to unlock			-0.50%
Technical	Upgrade to unlock			+0.46%

Rest of Alpha Signals: -0.56%

APVO probability advantage of beating the market (3M)Total:-9.62%
APVO AI Score

Significant changes Vs previous day

APVO Short Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$4.49
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro)
Take Profit:$XXXXXPro (XXXXX
Pro
)

APVO Proven Sell Signal & Price Forecast

This is the price chart for APVO from January 2, 2026 until today. The chart indicates, in red, the 113 days when the stock received a Sell/Strong Sell rating (sell signals, AI Score 1 to 3).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Sell signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Sell signals

Forecast:

1 Month
3 Months
6 Months
1 Year

APVO Average Past Performance & Loss Rate

Three months after its 1974 Sell signals since July 2026, APVO had an average performance of xxxxxxx and a xxxxxx Loss rate (negative performance).

1974 Past APVO Sell Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				-8.90%
Average Alpha				-22.76%
Loss Rate (% Negative Perf.)				77.25%
% Negative Alpha				77.36%

APVO Frequently Asked Questions

Will Aptevo Therapeutics stock go up?
According to Danelfin AI, Aptevo Therapeutics has today an AI Score of 2/10 (Strong Sell rating), because its probability of beating the market in 3 months (41.20%) is -9.62% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for Aptevo Therapeutics stock?
Is it a good time to buy, sell, or hold Aptevo Therapeutics stock right now?
Is Aptevo Therapeutics undervalued right now?
What was the price range of Aptevo Therapeutics stock over the past 12 months?
What is going on with Aptevo Therapeutics stock in the last 3 months?
Does Aptevo Therapeutics offer dividend payments?
What is the current market capitalization of Aptevo Therapeutics?

Aptevo Therapeutics Inc Company Profile

Aptevo Therapeutics Inc. operates as a clinical-stage biotechnology firm with its main focus on the research and development of immunotherapeutic solutions for an array of cancer types in the United States. It leverages the potential of its proprietary platforms, ADAPTIR and ADAPTIR-FLEX, to create monospecific, bispecific, and multi-specific antibody variants capable of bolstering the human immune response against malignant cells.

The company's star anticancer candidate is APVO436, which is presently in Phase 1b/2 trials aimed at combating acute myelogenous leukemia. Furthermore, Aptevo is progressing with ALG.APV-527, a pioneering bispecific ADAPTIR candidate currently undergoing Phase 1 evaluation for combatting NSCLC (Non-Small Cell Lung Cancer), colorectal cancer, pancreatic cancer, breast cancer, head and neck cancers, and additional solid tumors.

In addition to these projects is APVO603: a preclinical dual agonistic bispecific ADAPTIR designed for multiple forms of solid tumors; APVO442, another groundbreaking bispecific candidate fashioned using the advanced ADAPTIR-FLEX technology also targeting multiple solid tumors; lastly APVO711 which functions as a powerful preclinical dual mechanism bispecific ADAPTIR option predominantly targeted towards prostate cancer.

This mission has been further supported through a strategic collaboration with Alligator Bioscience AB that allowed them to develop ALG.APV-527. A testament to its relatively recent roots but impressive growth track record,Aptevo Therapeutics Inc was first established in 2016 and now proudly calls Seattle, Washington its home.

Sector:
Country:United States
Industry:
Address:2401 4th Ave Ste 1050, Seattle
Employees:33
Website:aptevotherapeutics.com

Pros

Proprietary immunotherapeutic platform technology

Potential for high pricing power for novel therapies

Long patent exclusivity for successful drug candidates

High switching costs for established chronic therapies

Addressing unmet medical needs in oncology

Cons

Extremely high capital intensity for drug development

Low probability of success in clinical trials

Lengthy and complex regulatory approval processes

Reliance on intellectual property protection and enforcement

Pipeline concentration risk in early-stage assets

Company	AI Score	Compare
APLMApollomics Inc
VORVor Biopharma Inc
APGEApogee Therapeutics Inc
IOVAIovance Biotherapeutics Inc
ARTVArtiva Biotherapeutics Inc

Company	AI Score	Compare
APLMApollomics Inc
VORVor Biopharma Inc
APGEApogee Therapeutics Inc
IOVAIovance Biotherapeutics Inc
ARTVArtiva Biotherapeutics Inc

APVO Stock AI Analysis High Risk